WASHINGTON, March 21, 2013 /PRNewswire-USNewswire/ -- The Consumer Healthcare Products Association (CHPA) released the following statement today on a recent poll of South Carolina voters conducted by Basswood Research and supported by CHPA. The poll, which surveyed 600 South Carolina voters March 13-14 , found that a 69-percent-majority of South Carolinians oppose a proposed law that would require all consumers to obtain a doctor's prescription before buying safe and effective cold and allergy medicines containing pseudoephedrine (PSE). Similarly, a 57% majority said it would be somewhat or very inconvenient to obtain a prescription for those popular medicines.
"The findings of the recent South Carolina poll are consistent with what we've seen across the country," said Carlos Gutierrez , senior director of state government affairs for CHPA. "Law-abiding consumers oppose the prescription-only approach because it leads to significant economic burdens produced by unnecessary time off work, additional copays, and increased fuel costs. According to the Asthma and Allergy Foundation of America, 18 million American households rely on PSE-based medicines for relief from common cold and seasonal allergy symptoms."
In January 2011, South Carolina launched a balanced solution in the fight against methamphetamine criminals. Known as the National Precursor Log Exchange, the real-time, stop-sale system allows retailers and pharmacists to block unlawful PSE sales in real time—just like a credit card transaction. In a little over two years since the system was implemented across the state, NPLEx has already blocked tens of thousands of possible illegal sales in the Palmetto State, and helped law enforcement officials execute numerous meth busts, arrests, and convictions. Despite the system's progress, some
SOURCE Consumer Healthcare Products Association
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
2. Chimerix Files Registration Statement for Proposed Initial Public Offering
3. CHPA Statement on PSE Economic Study By AEI Fellow Alex Brill
4. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
5. CHPA Statement on Statewide Indiana Consumer Poll
6. Sonitus Medical Announces Affirmative Update Regarding Bone Conduction Oral Appliances in American Academy of Otolaryngology-Head and Neck Surgery Policy Statement on Implantable Hearing Devices
7. Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
8. Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
9. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
10. Hill-Rom Reports Fiscal First Quarter Results; Updates 2013 Financial Outlook For R&D Tax Credit Reinstatement
11. CVS Caremark Statement and Response to CMS Action